Compare MPLX LP (MPLX) vs Pfizer Inc (PFE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
MPLX LP vs Pfizer Inc — how do they compare? MPLX LP trades at $57.42 (market cap $58.11B), while Pfizer Inc trades at $27.83 (market cap $158.56B). The key difference: Pfizer Inc is far larger — about 2.7× MPLX LP's market cap, and MPLX LP pays the higher dividend (7.51%). Which is the better fit depends on your goals.
| MPLX | PFE | |
|---|---|---|
Market Cap | $58.11B | $158.56B |
Volume | 687,483 | 44,138,282 |
Sector | Energy | Health |
52-Week High | $60.51 | $29.02 |
52-Week Low | $47.80 | $23.67 |
Enterprise Value | $83.22B | $210.06B |
Dividend Yield | 7.51% | 6.18% |
Typical Hold Time | — | 158 Days |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MPLX trades at $57.05, down 1.25% with a bearish technical signal. The company maintains strong profitability with 40.45% net income margin and 33.95% ROE, though recent earnings missed expectations in two consecutive quarters. Analyst consensus remains strongly bullish with a $63.80 price target, representing 12% upside potential. Recent news highlights MPLX's resilience in volatile energy markets through fee-based revenue models and strong distribution coverage.
The outlook remains positive given strong cash flow generation and dividend sustainability, though risks include energy market volatility and recent earnings misses. With 68% analyst buy ratings and solid fundamentals, MPLX presents a compelling income opportunity despite near-term technical weakness and sector headwinds.
Pfizer (PFE) trades at $27.82, up 1.22% with a bullish technical signal from moving averages. The company shows stable revenue around $62-63B with consistent earnings beats in recent quarters. Analysts maintain a $29.40 consensus target with 40% buy ratings. Recent news highlights Pfizer's focus on obesity and oncology pipelines as key growth drivers.
Pfizer offers value with defensive cash flows and dividend stability, though patent cliffs and margin compression present challenges. The stock's current valuation appears reasonable relative to sector peers, with upside potential if pipeline developments succeed. Key risks include competitive pressures and regulatory hurdles for new drug approvals.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About MPLX LP
MPLX LP is a Master Limited Partnership (MLP) formed by Marathon Petroleum Corporation (MPC). It is a diversified, growth-oriented company primarily engaged in the gathering, processing, and transportation of natural gas and natural gas liquids (NGLs), as well as the transportation, storage, and distribution of crude oil and refined petroleum products. MPLX owns and operates a network of midstream energy infrastructure assets, providing essential services to the energy industry across the United States.
Read more on MPLX →About Pfizer Inc
Pfizer Inc. operates as a pharmaceutical company. The Company offers medicines, vaccines, medical devices, and consumer healthcare products for oncology, inflammation, cardiovascular, and other therapeutic areas. Pfizer serves customers worldwide.
Read more on PFE →
